Aiyu Chen

Aiyu Chen

Auto-generated profile, based on publicly available information

Aiyu Chen

Kaiser Permanente Southern California, Pasadena, CA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
CNClaudia Nau
Claudia Nau
KBKatia Bruxvoort
Katia Bruxvoort
RNRonald A. A. Navarro
Ronald A. A. Navarro
SCShari G. Chevez
Shari G. Chevez
THTiffany A. Hogan
Tiffany A. Hogan
STSara Tartof
Sara Tartof

12 April 2019 in Chemical Research in Chinese Universities
Verified
Journal Article
Open access
PDF file
ACAiyu Chen
Aiyu Chen
YLYongdong Liang
Yongdong Liang
JYJiao Ye
Jiao Ye
AHAi-Xi Hu
Ai-Xi Hu
WLWenwen Lian
Wenwen Lian
GDGuanhua Du
Guanhua Du
Twenty-seven novel chalcone derivatives were designed and synthesized as neuraminidase(NA) inhibitors. A concise suitable synthetic strategy was employed in the target compounds’ synthesis with relatively high yields. The synthesized compounds were evaluated for their inhibitory activities against the NA of influenza A virus in vitro. The results show that compound 9b possesses the most potent NA inhibitory activity. Structure-activity relationship studies indicate that the chalcone system and hydrogen bond donor substituent are significant for the NA inhibitory activity. And the chalcone derivatives containing pyran ring have better NA inhibitory activity than those without the pyran ring. In addition, molecular docking studies reveal that compounds 9b and 9u are in the good binding mode with Zanamivir binding sites. This study indicates that compound 9b could be selected as a potent compound for further structural optimization and development of novel NA inhibitors.

1 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EHErin E Hahn
Erin E Hahn
ACAiyu Chen
Aiyu Chen
EHEric C. Haupt
Eric C. Haupt
LLLindsay Joe Lyons
Lindsay Joe Lyons
THTalar Habeshian
Talar Habeshian
PGPatricia A. Ganz
Patricia A. Ganz
36 Background: Risk-stratified survivorship care pathways are critical for meeting needs of cancer survivors and the oncology workforce. To support a clinical trial evaluating a survivorship model that transitions low-risk survivors to a primary care physician (PCP)-led survivorship clinic within an integrated healthcare system, we captured data on real-time clinical risk stratification of low-risk patients potentially eligible between 6 and 36 months after treatment cessation. Methods: After oncology stakeholder input, we developed a screening algorithm to identify low-risk breast and colorectal cancer (CRC) survivors from the electronic medical record based on data from pathology, treatment, and utilization records. The algorithm identified patients meeting study eligibility criteria: adult stage 0-IIb breast cancer or stage I-II CRC patients diagnosed with first primary cancer, excluding those with treatments indicative of high-risk or metastatic disease, ongoing ovarian suppression or trastuzumab treatment (breast), neoadjuvant chemotherapy (breast), or enrollment in other cancer clinical trials. Next, the treating oncologist was asked to confirm or deny patient eligibility based on low-risk criteria; if denied, ineligibility reason was requested. Characteristics and proportions of low-risk patients confirmed/denied eligibility and reasons for ineligibility are summarized. Results: 530 patients were identified and evaluated: 488 breast and 42 CRC. Mean age was 61 years (SD: 11.6, range 23-95); 96% female; 22% had stage 0 disease (breast only), 51% stage I, and 28% stage II. By cancer type, 390 breast patients were deemed eligible (80%); 31 CRC patients were eligible (74%). A greater proportion of Asian and Black patients were categorized eligible vs. ineligible (13% vs. 9%, and 25% vs.14%, respectively), and a smaller proportion of Hispanic and White were categorized eligible (26% vs. 33%, and 31% vs. 42%, respectively). Reasons for ineligibility included: suspicious for recurrence (6%), new primary disease (3%), complex case/condition (36%), patient preference (34%), and other/none (22%). “Complex case/condition” included reasons such as intolerance of chemotherapy, patient declined chemotherapy and/or endocrine treatment (breast), co-occurring hematology disorder; “other/none” included reasons such as current pregnancy Lynch syndrome, and no reason. Conclusions: Oncologists confirmed eligibility for 80% of algorithm-identified low-risk patients for referral to the PCP-led survivorship clinic. Of those ineligible, patient preference and complex case/condition were the most common reasons reported for ineligibility. Consensus-based risk algorithms supported by clinician review can quickly and effectively perform case identification of low-risk patients who may be appropriately transitioned to other settings for survivorship care.